Health
Generic chemotherapy injectables and specialty oncology drugs with severe supply concentration and no therapeutic substitutes.
Why it matters · Treatment delays and rationing at cancer centers when generic injectable chemo is unavailable; directly life-threatening.
14
Inputs
46
Companies
41
Facilities
10
Source countries
How it's made
API synthesis / upstream bioprocessing
Small molecules: multi-step organic synthesis of kinase inhibitors, platinum salts, and semi-synthesis of taxanes/camptothecins from botanical extracts. Biologics: CHO cell culture in 500–25,000 L bioreactors with single-use bag technology over 10–18 day fed-batch runs.
Harvest & clarification
Biologics: centrifugation + depth filtration to remove cells and cell debris. Small molecules: crystallisation, centrifugation, and drying of API.
Purification
Biologics: three-column chromatography platform — Protein A capture (removes ~99.9% host-cell proteins), ion exchange polishing, hydrophobic-interaction polishing; viral inactivation and 20 nm viral filtration integrated. Small molecules: recrystallisation, column chromatography.
Formulation & fill-finish
Drug substance concentrated/diafiltered (UFDF); formulated with stabilisers; 0.2 μm sterile-filtered and aseptically filled into Type I borosilicate vials or prefilled syringes under isolator/RABS conditions. CAR-T: formulated in CryoStor CS10 and filled into cryobags at -80°C to -196°C.
Quality control & regulatory release
Extensive in-process and final-product testing: potency, purity, sterility, endotoxin, aggregation, particle count. Regulatory release testing per Ph.Eur / USP. Biologics: 4–8 week release cycle.
Cold chain distribution
mAbs and injectable chemotherapy: 2–8°C refrigerated distribution. Lyophilised products: ambient. CAR-T autologous products: liquid-nitrogen vapor-phase (-150 to -196°C) in validated Dewar dry shippers; each shipment is a unique N=1 patient consignment.
What it's made of
14 raw inputs feed cancer and specialty drugs. Inputs flagged with ● are critical, without them, production halts.
manufactured
●manufactured
●manufactured
●pharmaceutical
●manufactured
●manufactured
●agricultural
●manufactured
mineral
agricultural
●chemical
pharmaceutical
●pharmaceutical
manufactured
●Where it comes from
Weighted share of upstream inputs sourced from each country.
| Country | Weighted share | Inputs supplied to cancer and specialty drugs |
|---|---|---|
| SESweden | 53% | Single-use bioreactor bags · Protein A chromatography resin (mAb) |
| CNChina | 33% | Single-use bioreactor bags · Camptothecin (botanical extract) · Cisplatin / carboplatin API +2 |
| USUnited States | 33% | Single-use bioreactor bags · Camptothecin (botanical extract) · CAR-T cryogenic dry shipper +6 |
| ZASouth Africa | 32% | Cisplatin / carboplatin API · Platinum group metal (pharmaceutical grade) |
| IEIreland | 30% | Sterile filtration membrane (0.2 μm) |
| INIndia | 24% | Camptothecin (botanical extract) · Cisplatin / carboplatin API · 10-Deacetylbaccatin III (10-DAB) +1 |
| DEGermany | 19% | Single-use bioreactor bags · CHO cell culture media · Cisplatin / carboplatin API +4 |
| CHSwitzerland | 13% | Lipid nanoparticle (LNP) lipid components · Platinum group metal (pharmaceutical grade) |
| ITItaly | 11% | Camptothecin (botanical extract) · 10-Deacetylbaccatin III (10-DAB) · Platinum group metal (pharmaceutical grade) +1 |
| BEBelgium | 11% | Platinum group metal (pharmaceutical grade) |
Shipped finished
Countries that ship finished cancer and specialty drugs directly to the U.S., distinct from the upstream raw inputs above.
| Country | U.S. imports | Share of U.S. imports |
|---|---|---|
| IEIreland | $19.1B | 24% |
| DEGermany (Federal Republic of Germany) | $17.8B | 23% |
| NLNetherlands | $7.2B | 9% |
| SGSingapore | $5.7B | 7% |
| BEBelgium | $5.6B | 7% |
| FRFrance | $5.1B | 6% |
| JPJapan | $4.6B | 6% |
| CHSwitzerland | $3.0B | 4% |
| ITItaly | $2.5B | 3% |
| KRSouth Korea (Republic of Korea) | $2.1B | 3% |
Who makes it
46 companies in this supply chain, sorted by market share.
Supplies these inputs
Repository Corticotropin Injection (Acthar Gel / Porcine ACTH)
Business segments
Supplies these inputs
CAR-T cryogenic dry shipper
Business segments
Life sciences tools company (Marlborough, MA; wholly-owned by Danaher Corporation since $21.4B acquisition of GE Healthcare Life Sciences in 2020) that manufactures Whatman membrane filter papers and sterile filtration products alongside its dominant chromatography resin (Capto, Sephadex, Sepharose series) and bioreactor (WAVE, XDR) platforms. Cytiva is the successor to GE Healthcare Life Sciences and Amersham Biosciences. Whatman-branded products include nitrocellulose and mixed cellulose ester membranes used in sterile filtration, diagnostics, and laboratory applications. Cytiva's role in sterile filtration is secondary to Merck KGaA and Pall — Whatman filters are more prevalent in laboratory/QC applications than primary pharmaceutical manufacturing sterilization — but Cytiva's ownership alongside Pall within Danaher creates the world's most concentrated supply position in biopharmaceutical manufacturing consumables. Danaher's combined Pall + Cytiva platform spans filtration, chromatography, bioreactors, and cell culture media — covering essentially every critical consumable step in a biologics manufacturing process.
Supplies these inputs
Single-use bioreactor bags · CHO cell culture media · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm)
Replaceability
Substitutability 8% · 12 mo to replace
Business segments
Intas Pharmaceuticals (Ahmedabad Gujarat India; privately held; founded 1976 by Hasmukh Chudgar; ~$2.4B revenue est. 2022) is the world's largest manufacturer of cisplatin and carboplatin APIs and one of India's largest private pharmaceutical companies. Intas operates its international generic injectable business under the brand Accord Healthcare (UK-registered subsidiary). Intas's Ahmedabad/Sanand API manufacturing complex in Gujarat was the single most important source of cisplatin API for the US market, supplying an estimated 50-60% of US cisplatin imports from its Gujarat facilities. In November 2022, FDA investigators conducting a pre-approval inspection at Intas's Ahmedabad manufacturing facility (FEI 3003889748) discovered hundreds of trash bags filled with shredded quality-control documents — evidence of deliberate document destruction intended to conceal data integrity violations. FDA issued a Form 483 with 10 observations. The FDA subsequently issued a Warning Letter in December 2022. Intas voluntarily ceased API production at the facility. The resulting API supply gap triggered the worst US oncology drug shortage in a decade, beginning in February 2023 for cisplatin and April 2023 for carboplatin. The Intas-Accord shortage became the central case study for pharmaceutical supply chain concentration risk.
Supplies these inputs
Cisplatin / carboplatin API
Replaceability
Substitutability 35% · 12 mo to replace
Business segments
Indian generics maker; its Accord/Intas units made roughly half of US cisplatin/carboplatin until a 2023 FDA inspection halt triggered a national shortage.
Supplies these inputs
Generic Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel)
Replaceability
Substitutability 30%
Business segments
Supplies these inputs
CHO cell culture media · Lipid nanoparticle (LNP) lipid components · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm)
Business segments
German science and technology company (Darmstadt; family-owned since 1668; ~€22B revenue; XETRA: MRK) whose life sciences division (MilliporeSigma in North America) is the world's largest manufacturer of pharmaceutical-grade sterile filtration membranes and filter devices. Merck KGaA's filtration product lines include Durapore (PVDF, hydrophilic, 0.22 μm and 0.45 μm) — the dominant membrane for protein and buffer sterilization — and Millipore Express PLUS/SHC/SHR (PES/modified PES) for high-flow biopharmaceutical applications. Sterilizing filter devices (Millipak, Opticap XL) complete the product platform. Merck KGaA is estimated to hold ~35-40% of the global pharmaceutical sterilizing membrane market. Manufacturing is concentrated at Cork, Ireland (primary) and Jaffrey, NH and Billerica, MA (US). The Darmstadt parent that makes Durapore sterilizing filters also produces liquid crystals for LCD displays, OLED materials, photoresists for semiconductor lithography, and specialty chemicals for cosmetics — a 350-year-old German family business operating across pharmaceutical manufacturing and consumer display technology from the same corporate parent.
Supplies these inputs
Single-use bioreactor bags · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm)
Replaceability
Substitutability 10% · 18 mo to replace
Business segments
Supplies these inputs
CHO cell culture media · Lipid nanoparticle (LNP) lipid components · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm)
Business segments
German pharmaceutical glass specialist (FRA: 1SXP; IPO September 2023 at ~€3.6B market cap); subsidiary of SCHOTT AG, which is wholly owned by the Carl Zeiss Foundation — a non-profit foundation structure that has owned SCHOTT since 1884. SCHOTT Pharma is the world's largest manufacturer of pharmaceutical primary packaging glass, holding an estimated 35-45% of the global pharmaceutical borosilicate glass tubing market from which vials, ampoules, and syringes are drawn. Type I borosilicate glass has been SCHOTT's core product since founder Otto Schott invented borosilicate glass composition in 1884, and SCHOTT has the longest continuous manufacturing history of any pharmaceutical glass maker. Key pharmaceutical glass vial production plants in Müllheim (Germany), Jena (Germany), Schweinfurt (Germany), and multiple international sites. Supplied hundreds of millions of vials for COVID-19 vaccine programs including BioNTech/Pfizer mRNA vaccines.
Supplies these inputs
Type I borosilicate glass vials
Replaceability
Substitutability 20% · 6 mo to replace
Business segments
Thermo Fisher Scientific (Waltham MA; NYSE: TMO; ~$43B revenue 2024) is the world's largest manufacturer of cell culture media through its Gibco brand — the dominant label in CHO (Chinese Hamster Ovary) cell culture media for biopharmaceutical manufacturing. Gibco CHO-S Serum-Free Medium, GlutaMAX supplement, CD CHO medium, and EX-CELL Advanced CHO media series supply the majority of global monoclonal antibody manufacturing processes. Thermo Fisher's cell culture media is manufactured primarily at its Grand Island, NY facility (acquired from Life Technologies, itself formerly GIBCO BRL), which is the single most important cell culture media manufacturing site in North America. Thermo Fisher also operates a major media production site in Paisley, Scotland (UK) that serves European biopharmaceutical manufacturing. Gibco media formulations are validated into more FDA-approved biologics manufacturing processes than any other supplier — creating regulatory lock-in equivalent to Cytiva's position in chromatography resins. The 2014 Thermo Fisher merger with Life Technologies (which itself had acquired Invitrogen in 2008 and GIBCO BRL in 2000) consolidated what were once multiple competing cell culture brands into a single dominant supplier.
Supplies these inputs
Single-use bioreactor bags · CHO cell culture media
Replaceability
Substitutability 8% · 18 mo to replace
Business segments
Chinese botanical extraction and pharmaceutical API company headquartered in Guangxi province — the heart of Camptotheca acuminata cultivation territory. Haoshu is among the largest producers of camptothecin and its hydroxylated derivative 10-hydroxycamptothecin (10-OHCPT) extracted from Camptotheca acuminata bark, wood, and leaves, and is a significant irinotecan API manufacturer supplying both domestic Chinese generic pharmaceutical companies and international API buyers. Guangxi's subtropical climate and rich red-clay soils support large Camptotheca acuminata plantations; Haoshu's vertical integration from plantation to API distinguishes it from pure chemical API manufacturers. The company also produces other phytochemical APIs from Chinese medicinal plant sources.
Supplies these inputs
Camptothecin (botanical extract)
Replaceability
Substitutability 25% · 60 mo to replace
Business segments
US filtration technology company (Port Washington, NY; wholly-owned by Danaher Corporation since 2015 acquisition for $13.8B; Danaher NYSE: DHR; ~$20B revenue). Pall is the world's second-largest pharmaceutical sterilizing filtration manufacturer with an estimated ~30% global market share. Key sterilizing membrane products: Supor (PES — polyethersulfone) membranes for high-protein and buffer applications; Fluorodyne (PVDF) for aggressive chemical compatibility. Filter devices include Kleenpak Nova, Ultipor N66, and Palltronic AerVent vent filters. Pall serves biopharma, biotechnology, food & beverage, and industrial sectors from the same filtration platform. Primary pharma manufacturing at Pensacola, FL and Fajardo, Puerto Rico. Danaher's simultaneous ownership of Pall (filtration, 30% biopharma market) AND Cytiva (chromatography resins and bioreactors, ~40% market) gives a single US industrial conglomerate unmatched consolidated control over the biopharmaceutical manufacturing consumables supply chain — a concentration with no historical precedent in the pharmaceutical equipment sector.
Supplies these inputs
Sterile filtration membrane (0.2 μm)
Replaceability
Substitutability 12% · 24 mo to replace
Business segments
German laboratory and bioprocessing equipment company (Göttingen; XETRA: SRT; ~€3.4B revenue) that manufactures Sartopore 2 (PES — polyethersulfone) and Sartopore Platinum (modified PES) sterilizing membranes — the primary European alternative to Merck/Pall membrane platforms. Sartorius holds an estimated ~15% share of the pharmaceutical sterilizing filtration market, with particular strength in European biologics manufacturing. Sartorius also makes Sartocon cassette systems for tangential flow filtration (TFF), Stedim biocontainers (single-use bags), and Biowave bioreactor systems — making it, like Danaher, a vertically integrated supplier across multiple critical biopharmaceutical manufacturing unit operations. Sartorius acquired Stedim (France) in 2007 and has organically grown its bioprocessing portfolio. Göttingen primary manufacturing; additional production in Yauco, Puerto Rico (acquired via Sartorius Stedim Biotech).
Supplies these inputs
Single-use bioreactor bags · CHO cell culture media · Sterile filtration membrane (0.2 μm)
Replaceability
Substitutability 15% · 12 mo to replace
Business segments
Swiss CDMO operating European and US API manufacturing sites; primary lipid partner for Moderna; manufactures SM-102 and full LNP lipid component portfolio including ionizable, PEGylated, phosphocholine, and plant sterols; claims largest complex lipid capacity globally
Supplies these inputs
Lipid nanoparticle (LNP) lipid components
Business segments
Merck KGaA (Darmstadt; family-owned since 1668; Life Science division ~$9B revenue) produces CHO cell culture media through its MilliporeSigma brand in North America and SAFC (Sigma-Aldrich Formulation & Custom manufacturing) globally. SAFC Biosciences is the custom media manufacturing arm that produces proprietary 'black box' formulations for major biopharmaceutical companies under NDA — meaning a significant fraction of industry media demand is manufactured exclusively by Merck KGaA under confidential contracts. Merck KGaA's media manufacturing sites include St. Louis, Missouri (Sigma-Aldrich legacy site) and Martillac, France (custom bioscience manufacturing). The same Merck KGaA Darmstadt organization manufactures EUV photoresists (display and semiconductor), liquid crystals for flat panels, and Fractogel chromatography resins — a German family-controlled conglomerate touching monoclonal antibody media, display materials, and semiconductor chemicals from one Hessen campus.
Supplies these inputs
CHO cell culture media
Replaceability
Substitutability 10% · 30 mo to replace
Business segments
Sterile injectables (Hospira) including propofol/anesthetics.
Supplies these inputs
Generic Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel)
Business segments
Hikma Pharmaceuticals PLC (Amman Jordan; London Stock Exchange: HIK; NYSE: WHL; ~$3.1B revenue) is a major US generic injectable pharmaceutical manufacturer primarily through its Hikma Pharmaceuticals USA (formerly Roxane Laboratories) division acquired in 2016 for $2.65B. US injectable manufacturing: Columbus OH (Hikma Columbus — formerly Roxane; large sterile injectable campus) and Eatontown NJ (Hikma Eatontown). Hikma produces morphine sulfate injection, fentanyl citrate injection, and hydromorphone HCl injection as Schedule II controlled substance generics for US hospitals. Hikma is the largest pure-play injectable pharmaceutical company by volume in the US generics market. Jordan-headquartered and London-listed but the business is majority US generic injectables — an unusual corporate structure for what is effectively a critical US hospital drug supplier.
Supplies these inputs
Generic Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel)
Business segments
Chinese pharmaceutical API manufacturer based in Shanxi province; significant producer of camptothecin API and related semi-synthetic intermediates. Shanxi Fenge processes camptothecin extracted from Camptotheca acuminata plant material sourced from cultivation regions (principally Guangxi, Fujian, and Jiangsu) and converts it to pharmaceutical-grade camptothecin powder used as a starting material for irinotecan and topotecan semi-synthesis. The company holds Chinese GMP certification and supplies API to Chinese generic drug manufacturers and international pharmaceutical buyers.
Supplies these inputs
Camptothecin (botanical extract)
Replaceability
Substitutability 25% · 48 mo to replace
Business segments
Where it's made
41 facilities producing inputs that feed cancer and specialty drugs.
Cytiva (Danaher) · Utah · manufacturing
Cytiva (formerly GE Healthcare Life Sciences) HyClone manufacturing facility in Logan UT — primary HyClone brand cell culture media production site. Originally HyClone Laboratories Inc. (founded Logan UT 1975); acquired by Thermo Fisher 2006; transferred to GE Healthcare Life Sciences 2014 as part of an asset swap; acquired by Danaher as part of the $21.4B Cytiva acquisition in 2020. Produces HyClone CDM4CHO, HyClone ActiCHO, and other serum-free CHO media. Source: https://www.cytiva.com/solutions/cell-culture
Cytiva (Danaher) · Michigan · manufacturing
Second Protein A resin site opened explicitly to reduce single-site concentration risk at Uppsala.
Cytiva (Danaher) · Uppsala County · resin-manufacturing
World's primary Protein A affinity resin manufacturing site. Former GE Healthcare Life Sciences Uppsala campus. Produces MabSelect SuRe, MabSelect PrismA, and Capto-series chromatography resins. Also manufactures Sepharose agarose bead base, single-use bioprocess bags, and crossflow filtration systems. Uppsala concentration is the most critical single-facility chokepoint in global mAb manufacturing.
Cytiva (Danaher) · Uppsala · manufacturing
Cytiva's primary Uppsala, Sweden bioprocess manufacturing campus — the world's most strategically critical single-use bioreactor bag production site. Manufactures Flexsafe STR bags (20L-2,000L), ReadyToProcess WAVE bags, chromatography resins (Capto, Sephadex), and filtration membranes. The Uppsala site was the primary global chokepoint for SU bag supply during the COVID-19 vaccine surge (2020-2021). The US government invoked the Defense Production Act in 2020 to require Cytiva to prioritize delivery of SU bags to US vaccine manufacturers (Pfizer, Moderna, J&J), to the disadvantage of European vaccine programs. Source: https://www.cytiva.com/company/manufacturing
Cytiva (Danaher) · Uppsala, Sweden · resin_manufacturing
Primary manufacturing site for Capto and Sephadex chromatography resins. Includes 3D printing (additive manufacturing) center for bioprocess hardware. Resins shipped globally to all major insulin and biologic manufacturers.
Dr. Reddy's Laboratories · Telangana · manufacturing
Dr. Reddy's Hyderabad API manufacturing complex; FDA-inspected facility producing irinotecan hydrochloride and other oncology APIs. Converts camptothecin starting material (sourced from China) to irinotecan via semi-synthetic route (camptothecin → 10-hydroxycamptothecin → irinotecan via controlled chemical transformation steps). The Hyderabad facility supplies irinotecan API for Dr. Reddy's own generic injectable finished dose manufacturing and for third-party generic pharmaceutical clients. Dr. Reddy's is among the top-3 generic irinotecan suppliers to the U.S. hospital formulary market. Source: https://www.drreddys.com/investors/annual-reports
Evonik Industries AG · Hesse · manufacturing
Primary GMP lipid component manufacturing for LNP-based drug delivery; supplied BioNTech COVID mRNA vaccine lipids; US BARDA committed up to $150M for US capacity expansion.
Fresenius Kabi AG · North Carolina · manufacturing
Large sterile fill-finish campus in Wilson NC; produces morphine sulfate, fentanyl citrate, and hydromorphone injectable vials for US hospital market under DEA Schedule II manufacturing quota. ISO 5 cleanroom fill-finish lines. Wilson NC is Fresenius Kabi's primary US injectable opioid manufacturing site. Received FDA Warning Letter for sterile manufacturing GMP deficiencies. Also produces IV fluids and parenteral nutrition from same campus.
Fujian Southeast Asia Biotechnology Co., Ltd. · Fujian Province · manufacturing
Fujian Southeast Asia Biotechnology paclitaxel API extraction and semi-synthesis facility in Fuzhou, Fujian Province. Sources 10-DAB from Yunnan and Fujian yew plantations. Produces paclitaxel API for Chinese finished-dose oncology manufacturers and Asian export markets. Source: https://www.fjdnysh.com
Fujifilm Irvine Scientific · California · manufacturing
Fujifilm Irvine Scientific primary manufacturing facility in Santa Ana CA (Orange County) — produces IS CHO-CD cell culture media series and specialty serum-free mammalian cell culture media. Also manufactures ART (assisted reproductive technology) media for IVF clinics globally. The same facility that makes Humira's cell culture media also makes the media used in human IVF procedures. Source: https://www.irvinesci.com/about/locations
Gerresheimer AG · Bavaria · manufacturing
Gerresheimer AG primary glass pharmaceutical packaging facility in Wackersdorf, Bavaria, Germany. Produces Type I borosilicate glass vials, ampoules, and prefillable syringes. Wackersdorf is Gerresheimer's largest European glass plant and one of Germany's major pharmaceutical glass manufacturing hubs. The Wackersdorf industrial zone was previously a proposed German nuclear reprocessing site (abandoned 1989 after protests) before being redeveloped for industrial manufacturing including Gerresheimer's pharma glass operations. Sources: Gerresheimer annual report 2023; company site map.
Haoshu International (Hao Shu Biotech) · Guangxi · cultivation
Primary Camptotheca acuminata plantation zone centered in Guangxi Zhuang Autonomous Region, China. Guangxi's warm subtropical climate, high humidity, and red-clay soils make it the most productive region for C. acuminata cultivation globally. Trees require 3-5 years of growth before meaningful alkaloid content is achieved. Bark, wood, leaves, and seed are all harvested; bark and wood have highest camptothecin concentrations (0.3-0.5% dry weight). Haoshu International and other extraction companies source plant material from Guangxi plantations. The region also hosts C. acuminata along roadsides and in forestry plots — a semi-wild cultivation pattern common for Chinese medicinal botanicals. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609381/
Hainan Poly Pharm Co., Ltd. · Hainan Province · manufacturing
Hainan Poly Pharm's primary API manufacturing facility in Haikou, Hainan Province; produces paclitaxel and docetaxel API via semi-synthesis from 10-DAB sourced from Taxus chinensis cultivated in Yunnan and Sichuan Province plantations. Source: https://www.polyp.com.cn
Indena S.p.A. · Lombardy · manufacturing
Indena's primary extraction and purification facilities in Milan and Settala (Lombardy). EMA GMP-certified; processes plant material imported from China and other botanical sources into camptothecin, paclitaxel, silymarin, and other phytochemical APIs. Indena's Italian GMP certification is a critical differentiator — it is the primary non-Chinese GMP-certified source for camptothecin-class compounds qualified for Western pharmaceutical manufacturing. Capacity is a fraction of Chinese producers but serves as the Western world's botanical extraction bridge. Source: https://www.indena.com/manufacturing-quality/manufacturing/
Indena S.p.A. · Lombardy · manufacturing
Indena's Milan and Settala (Lombardy) facilities produce 10-deacetylbaccatin III (10-DAB) and paclitaxel API via semi-synthesis from European yew (Taxus baccata) needle clippings sourced from European yew plantations. Also produces docetaxel, vincristine, vinblastine, and artemisinin from botanical sources. Indena's Milan operation is the largest European botanical pharmaceutical extract manufacturing site. Source: https://www.indena.com/our-facilities/
Intas Pharmaceuticals / Accord Healthcare · Gujarat · manufacturing
Intas Pharmaceuticals' primary API manufacturing complex in Ahmedabad, Gujarat (including the Sanand industrial estate satellite facility, ~30 km southwest of Ahmedabad city center). FDA FEI 3003889748. This facility was the world's single largest cisplatin API production site, supplying an estimated 50-60% of US cisplatin requirements. FDA investigators visited in November 2022 and discovered hundreds of trash bags of shredded quality-control documentation — evidence of systematic data integrity violations. FDA issued 10 observations in the Form 483 and a Warning Letter in December 2022. Intas voluntarily suspended API production. The shutdown triggered the US cisplatin shortage that began February 2023 and the carboplatin shortage that began April 2023. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-667094-12222022
Intas Pharmaceuticals / Accord Healthcare · Gujarat · manufacturing
Supplied ~50% of US cisplatin; FDA 2022 inspection found hundreds of trash bags of shredded quality-control documents; triggered 2023 US cisplatin and carboplatin shortages.
JSR Corporation · Ibaraki · resin-manufacturing
JSR Corporation's life sciences R&D and Amsphere A3 Protein A resin production facility in Tsukuba Science City, Ibaraki Prefecture. JSR's Protein A resin manufacturing capacity expanded significantly post-2020 in response to COVID-era bioprocessing demand surge. Tsukuba facility also produces JSR's semiconductor photoresist R&D materials.
Johnson Matthey Pharmaceutical Materials · Hertfordshire · lab
Johnson Matthey's Royston Hertfordshire facility produces pharmaceutical-grade specialty chemicals including controlled substance APIs under UK Medicines and Healthcare products Regulatory Agency (MHRA) authorization and INCB quota. JM Royston handles pharmaceutical precious metal and other specialty chemical manufacturing.
Luye Pharma Group Ltd. · Shandong Province · manufacturing
Luye Pharma Group's primary manufacturing complex in Yantai, Shandong Province; vertically integrated paclitaxel API production and finished-dose injectable oncology manufacturing. Produces paclitaxel injection, nab-paclitaxel (albumin-bound), and docetaxel formulations for Chinese and international markets. Source: https://www.luye.com/en/about
Mallinckrodt / SpecGx · Massachusetts · biologic_extraction
Merck KGaA (MilliporeSigma / SAFC Biosciences) · Missouri · manufacturing
Merck KGaA / MilliporeSigma / SAFC Biosciences St. Louis MO — legacy Sigma-Aldrich campus and primary North American SAFC custom and standard media manufacturing site. SAFC (Sigma-Aldrich Fine Chemicals / SAFC Biosciences) produces proprietary and custom CHO cell culture media under NDA for major biopharmaceutical companies. Sigma-Aldrich was acquired by Merck KGaA for $17B in 2015. Source: https://www.sigmaaldrich.com/US/en/applications/cell-culture-applications
Merck KGaA (MilliporeSigma) · Alsace · resin-manufacturing
Merck KGaA's primary bioprocess resin manufacturing site in Molsheim, Alsace France. Produces ProSep Ultra Plus (controlled-pore glass Protein A) and Eshmuno A (synthetic polymer Protein A) resins. Also produces Fractogel ion exchange resins. Molsheim is the #2 global Protein A resin production site by volume after Cytiva Uppsala.
Merck KGaA (MilliporeSigma) · County Cork · manufacturing
Merck KGaA / MilliporeSigma primary global membrane manufacturing site in Cork, Ireland. This is the world's largest single facility for pharmaceutical-grade PVDF (Durapore) and PES (Millipore Express) sterilizing membranes. The Cork site serves as the primary manufacturing origin for sterilizing-grade membrane used in global biopharmaceutical manufacturing. Cork was selected for its EU regulatory environment and skilled biotech/pharma workforce. A significant disruption at Cork would affect global sterile filtration supply within weeks given limited geographic redundancy. Source: https://www.emdmillipore.com/US/en/about/manufacturing/cork
Nipro Corporation · Osaka Prefecture · manufacturing
Nipro Pharma Corporation (Nipro subsidiary) pharmaceutical glass vial production in Osaka Prefecture, Japan. Primary site for Nipro's Japanese pharmaceutical glass vial output; serves both domestic Japanese pharmaceutical market and export markets. Nipro Pharma produces Type I borosilicate vials conforming to USP and JP (Japanese Pharmacopoeia) standards. Nipro is the largest pharmaceutical glass vial manufacturer in Japan and holds dominant share of the Japanese domestic parenteral packaging market. Source: https://www.nipropharma.co.jp/english/
Pall Corporation (Danaher) · Florida · manufacturing
Pall Corporation (Danaher) primary membrane manufacturing facility in Pensacola, FL producing Supor (PES) and Fluorodyne (PVDF) pharmaceutical-grade sterilizing membranes. Pensacola is Pall's largest US pharmaceutical filtration manufacturing site, serving the North American biopharmaceutical manufacturing customer base. The Pensacola facility is in the Gulf Coast hurricane zone — Category 3-5 hurricane risk has historically affected pharmaceutical supply chain planning for Pall customers. Ivan (2004) and Sally (2020) caused significant damage to Pensacola industrial facilities. Pall experienced documented production disruptions during major Gulf Coast storm events. Source: https://www.pall.com/en/about-pall/manufacturing-locations.html
Parker Hannifin (Bioscience Division) · County Durham · manufacturing
Parker Hannifin Bioscience Division membrane manufacturing at Birtley, County Durham, UK. The Birtley site (formerly domnick hunter filtration) produces pharmaceutical-grade PVDF and PES sterilizing membrane filters for European biopharmaceutical customers. Parker acquired domnick hunter in 2008 (£150M) to enter the pharmaceutical filtration market, gaining the Birtley manufacturing site and regulatory filings. The UK location provides Parker's European pharmaceutical customers with EU/UK GMP compliant sterilizing filter supply and extractables/leachables documentation packages necessary for regulatory submissions. Source: https://www.parker.com/en/divisions/bioscience-division.html
Pfizer Inc. (Hospira / Hospital Products) · Kansas · manufacturing
Large sterile injectable manufacturing facility in McPherson KS; Hospira legacy site producing fentanyl citrate injection, morphine sulfate injection, and hydromorphone HCl injection under DEA Schedule II quota. McPherson is one of Pfizer's largest US hospital injectable volume sites. Hospira had multiple FDA Warning Letters at McPherson prior to Pfizer acquisition; Pfizer remediated. Produces vials and prefilled syringes for hospital anesthesia and ICU use.
Phyton Biotech LLC · New York · manufacturing
Phyton Biotech's Port Jervis, New York plant is the world's largest plant cell fermentation (PCF) facility for paclitaxel API production. Uses large-scale bioreactors culturing Taxus plant cells to produce pharmaceutical-grade paclitaxel without yew tree logging. The only major US-located paclitaxel API production site. Supplies BMS (Taxol) and Fresenius Kabi generic oncology. Source: https://www.phytonbiotech.com/our-technology
Purolite (Ecolab Life Sciences) · Wales · resin-manufacturing
Purolite's primary Praesto Protein A resin manufacturing site in Pontyclun, Rhondda Cynon Taf, Wales. Produces Praesto AP (agarose Protein A), Praesto Jetted A50 (synthetic polymer), and Praesto AC (Protein A for continuous chromatography). Welsh facility also produces industrial ion exchange resins for Ecolab's water treatment business.
™Your Policy Risk Impact Agent